CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD | 10-Q: FY2025 Q1 Revenue: USD 0

Revenue: As of FY2025 Q1, the actual value is USD 0.

EPS: As of FY2025 Q1, the actual value is USD 0.

Segment Revenue

• Clinical Trial Supply Revenue: $0 for the three months ended March 31, 2025, compared to $29,000 for the same period in 2024.

Operational Metrics

• Operating Loss: - $5,036 for the three months ended March 31, 2025, compared to - $4,355 for the same period in 2024.
• Net Loss: - $81 for the three months ended March 31, 2025, compared to - $2,946 for the same period in 2024.
• Research and Development Expenses: $822 for the three months ended March 31, 2025, compared to $2,802 for the same period in 2024, a decrease of 71%.
• General and Administrative Expenses: $4,214 for the three months ended March 31, 2025, compared to $1,582 for the same period in 2024, an increase of 166%.

Cash Flow

• Net Cash Used in Operating Activities: - $3,247 for the three months ended March 31, 2025, compared to - $483 for the same period in 2024.
• Net Cash Provided by Financing Activities: $3,646 for the three months ended March 31, 2025, compared to - $79 for the same period in 2024.

Unique Metrics

• Gain on Deconsolidation of Subsidiary: $4,947 for the three months ended March 31, 2025.

Future Outlook and Strategy

• Core Business Focus: The company plans to focus on the development of the plogosertib clinical program, having repurchased related assets for approximately $0.3 million.
• Non-Core Business: The fadraciclib program is being marketed for sale, with no current plans to repurchase any rights or assets related to it.
• Going Concern: There is substantial doubt about the company’s ability to continue as a going concern, with plans to raise additional capital through private equity financing or strategic transactions.